Circassia Pharmaceuticals notified AstraZeneca that it will exercise its option to acquire the full US commercial rights to the Tudorza aclidinium DPI, the company said. Circassia acquired US rights to Tudorza and to Duaklir aclidinium/formoterol DPI in March 2017 in a deal that included 50/50 profit sharing with AstraZeneca. Completion of the option exercise, … [Read more...] about Circassia to exercise option to acquire full US rights to Tudorza aclidinium DPI
Business
Avanir to terminate license agreement for Onzetra Xsail intranasal sumatriptan
Avanir and Optinose have separately announced the termination of the license agreement that gave Avanir the North American rights to develop and commercialize Onzetra Xsail intranasal sumatriptan. The license agreement, which was initially announced in 2013, is expected to terminate on March 10, 2019. Onzetra Xsail was approved by the FDA in January 2016, and … [Read more...] about Avanir to terminate license agreement for Onzetra Xsail intranasal sumatriptan
Auris Medical’s intranasal betahistine gets orphan drug designation, expanded development
According to Auris Medical, the FDA has granted orphan drug designation to its intranasal betahistine for the treatment of obesity associated with Prader-Willi syndrome (PWS). The company also said that it has signed a letter of intent to in-license rights to US patents covering the use of betahistine for two other indications, depression and … [Read more...] about Auris Medical’s intranasal betahistine gets orphan drug designation, expanded development
Impel Neuropharma raises over $67 million for development of intranasal products
Intranasal drug developer Impel NeuroPharma has raised $67.5 million in a Series D financing round led by KKR and Norwest Venture Partners, the company said. Existing investors Vivo Capital, 5AM Ventures and venBio Partners also participated. According to Impel, the funds will be used to accelerate development of its pipeline of drugs based on its Precision Olfactory … [Read more...] about Impel Neuropharma raises over $67 million for development of intranasal products
Shionogi invests in inhaled nitric oxide powder developer Vast Therapeutics
Vast Therapeutics (formerly Novoclem) has announced that Shionogi & Co. was the sole investor in a Series A financing round that will fund pre-clinical and Phase 1 development of the company's dry powder nitric oxide for the treatment of respiratory infections in cystic fibrosis patients, with the expectation of a licensing agreement. The amount of the investment was … [Read more...] about Shionogi invests in inhaled nitric oxide powder developer Vast Therapeutics
Neurelis acquires Aegis Therapeutics
US Pharmaceutical company Neurelis, which recently submitted an NDA for Valtoco diazepam nasal spray, has acquired Aegis Therapeutics and its Intravail transmucosal absorption technology, a component of the Valtoco formulation. In addition to Intravail, Aegis Therapeutics offers two other excipients that can be used in nasal formulations, ProTek and Aegis Hydrogels, … [Read more...] about Neurelis acquires Aegis Therapeutics
Phase 3 trial of VR475 inhalation suspension fails to meet primary endpoint, Vectura discontinues development
Vectura has announced that a Phase 3 study of VR475 budesonide inhalation suspension for the treatment of severe uncontrolled asthma in adult and adolescent patients failed to meet its primary endpoint. As a result, the company said that it would discontinue development of VR475 (formerly known as Favolir), which it acquired when it acquired Activaero in … [Read more...] about Phase 3 trial of VR475 inhalation suspension fails to meet primary endpoint, Vectura discontinues development
InCarda Therapeutics raises $42 million, initiates Phase 2 trial of inhaled flecainide
InCarda Therapeutics has announced the completion of an oversubscribed $42 million Series B financing that will fund a Phase 2 study of InRhythm inhaled flecainide for the treatment of recent-onset paroxysmal atrial fibrillation (PAF). The financing round was led by Sofinnova and HealthCap, both new investors along with Deerfield Management. In 2015, InCarda raised … [Read more...] about InCarda Therapeutics raises $42 million, initiates Phase 2 trial of inhaled flecainide
Vectura to develop generic versions of Ellipta DPIs with Hikma
Vectura and Hikma Pharmaceuticals have announced a deal for development and commercialization of generic versions of GSK's Ellipta dry powder inhalers. Hikma will pay Vectura $15 million up front, $5 million at the start of clinical manufacturing for the first product, up to $75 million in development milestones, a percentage of distributable share of net profit on … [Read more...] about Vectura to develop generic versions of Ellipta DPIs with Hikma
Covis Pharma acquires additional rights to Alvesco, Omnaris, and Zetonna from AstraZeneca
AstraZeneca has announced that Covis Pharma will pay $350 million up front for the rights to market Alvesco ciclesonide MDI and the ciclesonide nasal spray Omnaris and nasal MDI Zetonna outside of the US. The deal also includes up to $21 million in potential payments conditioned on sales over the 4 years beginning in 2019. Covis acquired US rights to Alvesco, Omnaris, … [Read more...] about Covis Pharma acquires additional rights to Alvesco, Omnaris, and Zetonna from AstraZeneca